Dose Insider / Analyses / Wegovy vs Mounjaro

Wegovy vs MounjaroDifferent Drugs, Different Approved Uses, and What the Head-to-Head Trials Found

Updated November 20, 2026 · 34 min read · FDA labels 2026, SURMOUNT-5, SURPASS-2

Wegovy and Mounjaro are different drugs from different companies.

13.7% · 20.2%average weight lost on semaglutide at Wegovy's dose and on tirzepatide in the 72-week head-to-head trial
Average weight lost in 72 weeksHead-to-head obesity trial, % of starting weightTirzepatide20.2%Semaglutide13.7%Average weight lost in 72weeksHead-to-head obesity trial, % of starting weightTirzepatide20.2%Semaglutide13.7%

Semaglutide was given at the Wegovy dose; tirzepatide is the drug in Mounjaro.

On this page

Wegovy is semaglutide, approved to reduce weight from age 12, to lower cardiovascular risk in adults with obesity or overweight, and for a liver disease. Mounjaro is tirzepatide, approved to improve blood sugar control in type 2 diabetes from age 10. The two molecules have been compared directly twice, and tirzepatide produced more weight loss both times.

This page sets the two labels side by side: the approved uses, the two head-to-head trials, what each product did in its own trials, side effects, low blood sugar, the dose ladders on your calendar, and the prices on November 20, 2026.1,2

Are Wegovy and Mounjaro the same kind of drug?

They are related and not identical. Semaglutide, the drug in Wegovy, activates the receptor for the hormone GLP-1. Tirzepatide, the drug in Mounjaro, activates that receptor and a second one, the receptor for GIP.1,2 Both are injected once a week, and Wegovy also exists as a daily tablet.

WegovyMounjaro
DrugSemaglutideTirzepatide
Acts onGLP-1 receptorGIP and GLP-1 receptors
MakerNovo NordiskEli Lilly
Approved forWeight reduction; cardiovascular risk with obesity or overweight; MASH with liver fibrosisBlood sugar control in type 2 diabetes
AgesAdults; from 12 for weightAdults and children from 10
Injection doses0.25, 0.5, 1, 1.7, 2.4 mg; 7.2 mg2.5, 5, 7.5, 10, 12.5, 15 mg
Other formsDaily tablet, 1.5 to 25 mgNone
Half-lifeAbout 1 weekAbout 5 days
Self-pay price$349 a month; $399 for 7.2 mgNone published

Wegovy and Mounjaro prescribing information; manufacturer price pages read November 20, 2026.1,2,5,6

How the four brand names fit together

Two molecules are each sold under two names, one for diabetes and one for weight.1,2,7,8

For type 2 diabetesFor weight
Semaglutide, Novo NordiskOzempic, up to 2 mgWegovy, 2.4 mg and up to 7.2 mg
Tirzepatide, Eli LillyMounjaro, up to 15 mgZepbound, up to 15 mg

Wegovy against Mounjaro crosses both lines of this table: a different molecule and a different use. The matching comparisons are Ozempic vs Mounjaro, both for diabetes, and Wegovy vs Zepbound, both for weight. The mirror image of this page is Ozempic vs Zepbound.

What exactly is each approved for?

Wegovy has three approved uses, each combined with a reduced-calorie diet and more physical activity.1

Mounjaro has one: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes.2

Neither list contains the other's main use. Wegovy is not approved for blood sugar control, and Mounjaro is not approved for weight reduction. The tirzepatide product approved for weight is Zepbound.8

SituationLabel that names it
Obesity, or overweight with a weight-related condition, adultsWegovy
Obesity, age 12 to 17Wegovy
Cardiovascular disease with obesity or overweightWegovy
MASH with moderate to advanced fibrosisWegovy
Type 2 diabetes, blood sugar control, adultsMounjaro
Type 2 diabetes, age 10 to 17Mounjaro

What each product is approved for. It is not a recommendation.1,2

A person with type 2 diabetes and obesity fits both labels. The Wegovy label covers that case with one instruction: in patients with diabetes, blood sugar is monitored before starting and during treatment.1

Have semaglutide and tirzepatide been compared directly?

Twice, once in obesity and once in diabetes. Neither trial used both of these brand names, so it helps to say exactly which doses were tested.3,4

SURMOUNT-5SURPASS-2
Who751 adults with obesity, without diabetes1,879 adults with type 2 diabetes on metformin
Length72 weeks40 weeks
Semaglutide dose1.7 or 2.4 mg, doses of Wegovy1 mg, a dose of Ozempic
Tirzepatide dose10 or 15 mg5, 10 or 15 mg
Weight, semaglutide−13.7%−5.7 kg
Weight, tirzepatide−20.2%−7.6, −9.3 and −11.2 kg
Waist, semaglutide and tirzepatide−13.0 cm and −18.4 cm
HbA1c, semaglutide and tirzepatide−1.9 points; −2.0, −2.2 and −2.3 points

Aronne 2025 and Frías 2021.3,4

The two direct trialsSURMOUNT-5, SURPASS-2
Trial

The obesity trial reports percent of body weight; the diabetes trial reports kilograms in people who averaged about 94 kg. Both trials were open-label, and the obesity trial was funded by the maker of tirzepatide.

The obesity trial is the one that used Wegovy's doses. People were brought to the highest dose they could tolerate, 1.7 or 2.4 mg of semaglutide or 10 or 15 mg of tirzepatide. Weight fell 13.7% on semaglutide and 20.2% on tirzepatide, and people on tirzepatide were more likely to lose at least 10%, 15%, 20% and 25% of their weight.3

The diabetes trial is the one in Mounjaro's population. Against semaglutide 1 mg, tirzepatide produced 1.9 kg more weight loss on 5 mg, 3.6 kg more on 10 mg and 5.5 kg more on 15 mg, and lowered HbA1c by 2.0 to 2.3 points against 1.9. At the end, 79% of people on semaglutide and 82% to 86% on tirzepatide had an HbA1c below 7%.4

Three limits apply to reading these as Wegovy against Mounjaro. The obesity trial enrolled people without diabetes, who are not the people Mounjaro is approved for. The diabetes trial tested semaglutide at 1 mg, well below Wegovy's 2.4 mg. And both were open-label, meaning people knew which drug they were taking; the obesity trial was funded by Eli Lilly.3,4

In both trials the most common adverse events were in the stomach and gut. In the obesity trial most were mild to moderate and came mainly while the dose was being raised.3 In the diabetes trial blood sugar below 54 mg/dL was reported by 0.4% on semaglutide and by 0.6%, 0.2% and 1.7% on tirzepatide 5, 10 and 15 mg.4

What did each do in its own label trials?

Each label reports what its drug did against placebo, in the people it was meant for.1,2

Trial in the labelWhoResultPlacebo
Wegovy 2.4 mg, 68 weeksObesity or overweight with a related conditionWeight −14.9%−2.4%
Wegovy 2.4 mg, 68 weeksType 2 diabetes with obesity or overweightWeight −9.6%−3.4%
Wegovy 2.4 mg, 68 weeksWith intensive lifestyle therapyWeight −16%−5.7%
Mounjaro 5 mg, 40 weeksType 2 diabetesHbA1c −1.8 points; weight −6.3 kg−0.1 points; −1.0 kg
Mounjaro 10 mg, 40 weeksType 2 diabetesHbA1c −1.7 points; weight −7.0 kg−0.1 points; −1.0 kg
Mounjaro 15 mg, 40 weeksType 2 diabetesHbA1c −1.7 points; weight −7.8 kg−0.1 points; −1.0 kg

Wegovy prescribing information, Table 8, and Mounjaro prescribing information, Table 4.1,2

Mounjaro's weight results are in kilograms. From the average starting weights in the same table they come to 7.2%, 8.1% and 9.1% of body weight for the three doses, by our arithmetic.2

On these label figures Wegovy looks ahead, 14.9% against 9.1%, which is the opposite of what the direct trial found. The explanation is in the trials. Wegovy's ran 68 weeks against 40. Its main trial enrolled people without diabetes, and Wegovy's own trial in people with diabetes found 9.6%, almost the same as Mounjaro's top dose in a shorter trial. And tirzepatide's weight-loss trials, run under the name Zepbound for 72 weeks in people without diabetes, found 15% to 20.9%.1,2,8

The fair comparison of the molecules for weight is therefore the head-to-head trial: 20.2% on tirzepatide against 13.7% on semaglutide over 72 weeks.3

Tirzepatide's own weight trials

Because Mounjaro's trials were not built to measure weight, the tirzepatide figures that correspond to Wegovy's come from the Zepbound label, where the same drug at the same doses was tested for 72 weeks in adults with obesity or overweight.8

Lost at leastWegovy 2.4 mg, 68 weeksTirzepatide 5 mg, 72 weeks10 mg15 mg
Average loss14.9%15.0%19.5%20.9%
5%83.5%85.1%88.9%90.9%
10%66.1%68.5%78.1%83.5%
15%47.9%48.0%66.6%70.6%

Wegovy prescribing information, Table 8, and Zepbound prescribing information, Table 2. Separate trials in people without diabetes.1,8

Read across separate trials, Wegovy 2.4 mg and the lowest long-term dose of tirzepatide, 5 mg, come out almost level, and the two higher doses pull ahead. That agrees with the direct trial, in which people on tirzepatide were taken to 10 mg or 15 mg.3

With intensive lifestyle therapy added for everyone, the Wegovy label reports 16% against 5.7% on placebo, and at least 15% lost by 53.4% against 13.2%.1

How many people reached each weight threshold on Wegovy?

Wegovy 2.4 mg, 68 weeksLost 5% or moreLost 10% or moreLost 15% or more
Obesity or overweight with a related condition83.5%66.1%47.9%
Placebo in that trial31.1%12%4.8%
Type 2 diabetes with obesity or overweight67.4%44.5%25.1%
Placebo in that trial30.2%10.2%4.3%

Wegovy prescribing information, Table 8.1

The Mounjaro label has no such table for weight, because weight was not what its trials were built to test. Its counterpart is the share reaching an HbA1c below 7%: 82% on 5 mg, 85% on 10 mg and 78% on 15 mg, against 23% on placebo.2

The same results with placebo taken out

Part of every result belongs to the diet, the attention and the passage of time, which the placebo group measures. Subtracting it leaves the part attributable to the drug: 12.5 points for Wegovy in its main trial and 6.2 points in its diabetes trial, and 5.3, 6.0 and 6.8 kg for Mounjaro 5, 10 and 15 mg.1,2 The Mounjaro differences are the ones its label states.

What the trials asked people to do alongside the drug

In most of the Wegovy trials everyone, the placebo group included, was told to eat about 500 kcal a day less than they needed and was counseled to be active for at least 150 minutes a week. The trial with intensive lifestyle therapy went further: eight weeks on 1,000 to 1,200 kcal a day, then 1,200 to 1,800 kcal a day, with activity rising from 100 to 200 minutes a week.1 Mounjaro is approved as an addition to diet and exercise.2 The page on what to eat on a GLP-1 applies to both.

What do those results look like in my weight?

Enter your weight to see each trial's average loss as pounds or kilograms.

Each trial in my weightLabels and direct trial
Unit

Log your weight each week and see your own line next to these averages.

Open the app

Separate trials of different lengths in different people, apart from the last two bars, which are the two arms of one trial. The bars show trial averages, not what switching would do.

Who was in the label trials?

Wegovy, weight trialsMounjaro, main safety pool
People on the drug2,116718
LengthUp to 68 weeksAbout 37 weeks
ConditionObesity or overweight; 19% had type 2 diabetesType 2 diabetes, for 9.1 years on average
Average age4858
Women71%46%

Wegovy and Mounjaro prescribing information, section 6.1.1,2

The two groups differ in condition, in age and in the share of women, which is one practical reason the label rates cannot be laid side by side.1,2

Which lowers blood sugar more?

Mounjaro is the one approved for it, and its numbers are the larger ones. In its label trial as the only diabetes medicine, HbA1c fell 1.7 to 1.8 points over 40 weeks against 0.1 on placebo, and 78% to 85% of people finished below 7%, against 23%.2 In the direct trial against semaglutide 1 mg, tirzepatide lowered HbA1c by 2.0 to 2.3 points and semaglutide by 1.9.4

Wegovy is not approved for blood sugar control. Its label says the drug lowers blood glucose and can cause low blood sugar, tells prescribers to monitor blood sugar in people with diabetes, and lists low blood sugar in people with type 2 diabetes among its common reactions: 6% against 2% on placebo.1 The semaglutide product approved for blood sugar is Ozempic.7

Semaglutide's own diabetes trials

The semaglutide figures that correspond to Mounjaro's come from the Ozempic label. Over 30 weeks as the only diabetes medicine, HbA1c fell 1.4 points on 0.5 mg and 1.6 points on 1 mg, against 0.1 on placebo, and in the trial of the top dose it fell 2.1 points on 2 mg. Ozempic also has outcome evidence in diabetes: major cardiovascular events in 6.6% against 8.9% on placebo, and a kidney outcome in 18.7% against 23.2%.7 The page on Ozempic vs Mounjaro compares the two diabetes products.

Which has evidence for the heart and liver?

Wegovy has it in its label. Two of its three approved uses rest on outcome evidence.1

Wegovy trialWhoResult
Cardiovascular outcomes17,604 adults with cardiovascular disease and obesity or overweight, without diabetes, followed for a median of 41.8 monthsRisk of a first major event 20% lower than on placebo
Liver800 adults with MASH and stage 2 or 3 fibrosis, biopsies at 72 weeksThe basis of the MASH indication, approved under the accelerated pathway with a confirmatory trial still required

Wegovy prescribing information, sections 1 and 14.1

The cardiovascular trial counted cardiovascular death, non-fatal heart attack and non-fatal stroke, the events named in Wegovy's second approved use. Its participants had cardiovascular disease and obesity or overweight and did not have diabetes.1

The cardiovascular trial was long enough to show who stays on treatment: by its end 31% of people on Wegovy and 27% on placebo had permanently stopped the study drug.1

Mounjaro's label has one indication, blood sugar control, and no cardiovascular or liver indication.2 For a person with cardiovascular disease and obesity, Wegovy's label speaks to that situation directly. For blood sugar in type 2 diabetes, Mounjaro's does.

How do the dose ladders compare?

Both start low and step up every four weeks at the fastest. The numbers on the pens are not comparable: 2.4 mg of semaglutide and 15 mg of tirzepatide are doses of different drugs.1,2

WeeksWegovyMounjaro, at the fastest
1 to 40.25 mg2.5 mg
5 to 80.5 mg5 mg
9 to 121 mg7.5 mg, if needed
13 to 161.7 mg10 mg, if needed
17 to 202.4 mg12.5 mg, if needed
21 onward2.4 mg, or 7.2 mg after at least 4 weeks on 2.4 mg15 mg, if needed

Wegovy and Mounjaro prescribing information, section 2.1,2

Either ladder, my datesFDA labels
Drug

    Log each shot and the app keeps these dates for you.

    Open the app

    The earliest dates each label allows. Mounjaro's steps above 5 mg are taken only if more blood sugar control is needed. The prescriber decides each step.

    The logic of the two ladders differs. Wegovy's climbs to a maintenance dose that its label gives as either 1.7 mg or 2.4 mg for adults. Mounjaro's label starts at 2.5 mg, a dose it describes as not intended for blood sugar control, moves to 5 mg, and goes higher only when more control is needed.1,2 The pages on the Wegovy and Mounjaro schedules have each ladder in full.

    Which has more side effects?

    The same kinds on both, in the stomach and gut. The rates in the two labels come from very different trials, so they describe each drug in its own setting and cannot rank them.1,2

    Stomach and gut reactionsEach label's trials
    Reaction

    Wegovy: 68 weeks in adults with obesity or overweight. Mounjaro: about 37 weeks in adults with type 2 diabetes. Each drug bar belongs with its own placebo.

    ReactionWegovy trials: placebo, 2.4 mgMounjaro trials: placebo, 5, 10, 15 mg
    Nausea16%, 44%4%, 12%, 15%, 18%
    Diarrhea16%, 30%9%, 12%, 13%, 17%
    Vomiting6%, 24%2%, 5%, 5%, 9%
    Constipation11%, 24%1%, 6%, 6%, 7%
    Abdominal pain10%, 20%4%, 6%, 5%, 5%
    Stopped because of side effectsAny adverse reaction: 3.2%, 6.8%Stomach and gut reactions: 0.4%, 3%, 5.4%, 6.6%

    Wegovy prescribing information, Table 3, and Mounjaro prescribing information, Table 1.1,2

    Wegovy's figures are higher across the board, and so are its placebo figures: 16% of people on placebo reported nausea in the Wegovy trials and 4% in the Mounjaro trials.1,2 A trial that runs 68 weeks gives each person more time to report a reaction than one that runs about 37, and the two enrolled different people.

    The direct trial in diabetes is the cleaner comparison, at semaglutide's lower 1 mg dose. Over the same 40 weeks, nausea was reported by 18% on semaglutide and by 17% to 22% on tirzepatide, diarrhea by 12% and 13% to 16%, and vomiting by 8% and 6% to 10%. Serious adverse events were reported by 3% on semaglutide and 5% to 7% on tirzepatide.4

    Reaction by reaction

    Nausea. The most common reaction on both: 44% on Wegovy against 16% on placebo, and 12% to 18% on Mounjaro against 4%. A pooled analysis of the Wegovy trials found that a single episode lasted a median of 8 days.1,2,9

    Vomiting. Wegovy: 24% against 6%. Mounjaro: 5% on 5 mg and 10 mg and 9% on 15 mg, against 2%. Both labels tie persistent vomiting to dehydration and kidney injury.1,2

    Diarrhea. Wegovy: 30% against 16%. Mounjaro: 12% to 17% against 9%.1,2

    Constipation. Wegovy: 24% against 11%. Mounjaro: 6% to 7% against 1%. In the Wegovy trials an episode lasted a median of 47 days, far longer than the other reactions.1,2,9

    When do the side effects come, and how long do they last?

    On both drugs, while the dose is going up. The Mounjaro label says the majority of reports of nausea, vomiting and diarrhea occurred during dose escalation and decreased over time.2 For Wegovy a pooled analysis of its trials gives more detail: first events came mostly during the step-up, the share of people with nausea, diarrhea or vomiting peaked at about week 20 and declined afterwards, and constipation levelled off at about week 10.9

    That analysis also measured single episodes on Wegovy 2.4 mg: a median of 8 days for nausea, 3 days for diarrhea, 2 days for vomiting and 47 days for constipation. Of all stomach and gut events, 98.1% were mild or moderate, and they ended treatment for 4.3% of people against 0.7% on placebo.9 The Mounjaro label reports no durations.

    Are side effects a sign that the drug is working?

    No, on either drug. In the Wegovy trials, people who had no stomach or gut events lost 15.7% of their weight and those who had them lost 17.3%.9 In the five main Mounjaro trials, people who reported nausea, vomiting or diarrhea lost 6.2 to 14.9 kg and those who did not lost 6.2 to 13.3 kg.11

    Side effects outside the stomach, in each label

    ReactionWegovy trialsMounjaro trials
    Reactions at the injection site1.4% against 1% on placebo3.2% against 0.4%
    Hair loss3.3% against 1%Reported after approval, no rate
    Fatigue11% against 5%Not in the table
    Altered skin sensations2% against 1%; 22% on 7.2 mg0.4% at each dose, none on placebo
    Heart rateUp 1 to 4 beats a minuteUp 2 to 4 beats a minute, against 1 on placebo
    GallbladderGallstones in 1.6% against 0.7%Gallbladder disease in 0.6% against none
    Pancreatitis4 people, 0.2 per 100 patient-years, against 1 on placebo13 people, 0.23 per 100 years, against 0.11 on comparison treatments

    Wegovy prescribing information, sections 5 and 6.1, and Mounjaro prescribing information, section 6.1.1,2

    The Mounjaro label and the pooled analysis of the Wegovy trials both place most nausea, vomiting and diarrhea in the weeks when the dose was being raised.2,9 The pages on Wegovy side effects and Mounjaro side effects go through each label.

    Hair loss

    On Wegovy 2.4 mg it was reported by 3.3% of people, 4% of women and 0.9% of men, against 1% on placebo, and the label says it was associated with weight reduction.1 Mounjaro's trial tables do not include it; it appears among the reports received after approval.2 In tirzepatide's weight trials it was reported by 4% to 5% against 1%.8 The page on hair loss explains the link with weight loss.

    Less common reactions in each label

    Wegovy. Headache was reported by 14% against 10% on placebo, dizziness by 8% against 4%, altered taste by 1.7% against 0.5%, low blood pressure by 1.3% against 0.4% and fainting by 0.8% against 0.2%. Acute kidney injury occurred in 7 people on Wegovy and 4 on placebo, some of it together with stomach reactions or dehydration, and appendicitis in 0.5% against 0.2%.1

    Mounjaro. Allergic reactions were reported by 3.2% against 1.7% on placebo. Episodes of a fast heart rhythm with a rise of 15 beats or more occurred in 4.6%, 5.9% and 10% on 5, 10 and 15 mg, against 4.3%. Pancreatic amylase rose by an average of 33% to 38% and lipase by 31% to 42%, and the label says the meaning of those rises is unknown without other signs of pancreatitis.2

    In the long cardiovascular trial of Wegovy. Over a median of about three years, 16% of people on Wegovy and 8% on placebo stopped the drug because of an adverse event. Hip and pelvic fractures were more frequent on Wegovy among women, 1% against 0.2%, and among people aged 75 and older, 2.4% against 0.6%, and kidney stones were reported by 1.2% against 0.8%.1

    Are the warnings the same?

    Largely. Both labels carry a boxed warning about thyroid C-cell tumors, and both warn about pancreatitis, low blood sugar with insulin or a sulfonylurea, kidney injury from dehydration, severe stomach and gut reactions, allergic reactions, gallbladder disease, diabetic retinopathy and aspiration during anesthesia or deep sedation. Neither is recommended for people with severe gastroparesis.1,2

    Reported after approval

    The two labels list much the same reports from use outside trials: pancreatitis, ileus and intestinal obstruction, severe constipation including fecal impaction, serious allergic reactions, kidney injury and aspiration during procedures under anesthesia. Mounjaro's list also has hair loss. Both labels caution that such reports are voluntary, so their frequency cannot be reliably estimated and a causal link cannot always be established.1,2

    What the warnings ask you to watch for

    WarningWhat the labels say
    PancreatitisPersistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting
    Kidney injuryFollows dehydration; nausea, vomiting or diarrhea that persists should be reported
    GallbladderGallstones were more frequent on both drugs than on placebo
    Eyes, with diabetesIn a 2-year trial of semaglutide at lower doses, retinopathy complications occurred in 3% against 1.8% on placebo; Mounjaro's label says people with a history of retinopathy should be monitored
    AnesthesiaTell the team before a planned operation or procedure with anesthesia or deep sedation

    Wegovy and Mounjaro prescribing information, section 5.1,2

    Does either cause low blood sugar?

    Rarely alone, and more often together with insulin or a sulfonylurea.1,2

    Situation, readings below 54 mg/dLDrugPlacebo
    Wegovy 2.4 mg in type 2 diabetes6.2%2.5%
    Mounjaro alone, 40 weeks0% at each dose1%
    Mounjaro with basal insulin, 40 weeks16%, 19% and 14% on 5, 10 and 15 mg13%
    Mounjaro with a sulfonylurea, up to 104 weeks13.8%, 9.9% and 12.8%

    Wegovy prescribing information, section 6.1, and Mounjaro prescribing information, Table 2.1,2

    Severe episodes were rare on both. In the Mounjaro trials with basal insulin they were reported by 2% on 10 mg and 1% on 15 mg, and with a sulfonylurea by 0.5% on 5 mg and 0.6% on 15 mg. In the Wegovy trial one person on the drug had a severe episode and nobody on placebo.1,2

    In the Wegovy trial, the rate of episodes was 10.7 per 100 patient-years on 2.4 mg, 7.2 on semaglutide 1 mg and 3.2 on placebo.1 Both labels tell prescribers that the risk may be lowered by reducing the dose of the insulin or the sulfonylurea.1,2

    What does Wegovy's 7.2 mg dose change?

    It is a second step that Mounjaro's ladder has no equivalent for: after at least four weeks on 2.4 mg, the Wegovy label allows 7.2 mg. Its side effects were measured in two 72-week trials with 1,311 people on 7.2 mg, 304 on 2.4 mg and 303 on placebo.1

    ReactionPlaceboWegovy 2.4 mgWegovy 7.2 mg
    Nausea13%35%39%
    Vomiting6%16%22%
    Altered skin sensations0%6%22%
    Constipation8%19%20%
    Hair loss1%3%6%

    Wegovy prescribing information, Table 4.1

    The stomach reactions rise a little, and burning or tingling skin rises a great deal. Stopping because of adverse reactions was the same on the two doses, 5%, against 2% on placebo.1 The 7.2 mg dose costs $399 a month at NovoCare, against $349 for the lower doses.5

    What if a dose is late?

    The two labels state the rule differently and arrive at nearly the same window.1,2

    WegovyMounjaro
    Take the missed dose ifThe next scheduled dose is more than 2 days awayIt is within 4 days (96 hours) of the missed dose
    OtherwiseSkip it and take the next dose on the usual daySkip it and take the next dose on the usual day

    Wegovy and Mounjaro prescribing information, section 2.1,2

    A late dose, each labelLabel rules and model
    Days since the dose was due

    The levels come from our model, built on each label's half-life, for a settled dose. They are not blood tests.

    Counted in days after the missed dose, Wegovy's rule allows the late dose through day 4, since on day 5 the next dose is only 2 days away. Mounjaro's allows it through day 4 as well.1,2 The page on missed doses works through the days one by one.

    How long does each stay in the body?

    Semaglutide lasts longer. The Wegovy label gives it a half-life of about one week and says it remains in the circulation for about 5 to 7 weeks after the last injection.1 Tirzepatide has a half-life of about 5 days.2 By the arithmetic of five half-lives, that is about 25 days.

    Both drugs slow the emptying of the stomach. The Mounjaro label says the delay is largest after the first dose and diminishes over time, and tells people who use birth control pills to switch to a non-oral method or add a barrier method for 4 weeks after starting and after each dose increase.2 The Wegovy label contains no such rule for contraceptives.1

    Planning a pregnancy

    The Wegovy label says to stop it at least 2 months before a planned pregnancy, because the drug takes that long to leave the body.1 The pages on how the level moves through the week, how long tirzepatide stays in your system and tirzepatide and birth control have the detail.

    How do they compare in daily use?

    Closely. Each injection is given once a week, at any time of day, with or without meals.1,2 The differences are at the edges: Wegovy has a tablet and Mounjaro does not, Wegovy has a 7.2 mg step above its usual dose, a late Wegovy dose is judged by the time to the next dose and a late Mounjaro dose by the time since the missed one, and people on birth control pills have a 4-week rule on Mounjaro that Wegovy's label does not contain.1,2

    Both are built to last a week. The Mounjaro label attributes tirzepatide's long half-life to a fatty acid chain that lets it bind to albumin, a blood protein, and the Ozempic label gives albumin binding as the reason for semaglutide's.2,7

    Do age or kidney disease change the comparison?

    Teenagers. In Wegovy's trial in patients aged 12 and older, nausea was reported by 42% against 18% on placebo, vomiting by 36% against 10% and abdominal pain by 15% against 6%; gallstones were reported by 3.8% and nobody on placebo.1 In Mounjaro's trial in patients aged 10 and older with type 2 diabetes, vomiting was reported by 16% on 5 mg and 12% on 10 mg against 3%, and abdominal pain by 22% and 15% against 9%.2 On both drugs vomiting was more frequent in the young than in adults.

    Older adults. Few took part in Wegovy's weight trials: 9% of the people on the injection were aged 65 to 74 and 1% were 75 or older.1 In Mounjaro's larger pool 30.1% were 65 or older, and its label found no general difference in safety between them and younger patients, adding that greater sensitivity in some older people cannot be ruled out.2

    Kidney disease. Mounjaro needs no dose adjustment for reduced kidney function, and the Wegovy label reports no clinically relevant difference in the drug's level with kidney impairment.1,2 For both the practical concern is fluid: vomiting or diarrhea that leads to dehydration.

    How do the forms and storage differ?

    Wegovy's injection comes in pens, and the drug also exists as a daily tablet. Mounjaro comes as single-dose pens and vials and as multi-dose vials and KwikPens that hold four doses.1,2

    Wegovy single-dose penMounjaro single-dose pen or vial
    NormallyIn a refrigeratorIn a refrigerator, 36°F to 46°F
    Out of the refrigeratorUp to 28 days at 46°F to 86°F, before the cap is removedUp to 21 days in total at up to 86°F, then discard

    Wegovy and Mounjaro prescribing information, section 16.1,2

    The Wegovy tablet

    Only Wegovy has an oral form. The tablet is taken once a day in the morning on an empty stomach, with up to 4 ounces of water and no other liquid, and food, other drinks and other oral medicines wait at least 30 minutes. Its doses rise from 1.5 mg to 4 mg, 9 mg and 25 mg.1 In its trial the types and frequency of common reactions were similar to those of the injection.1

    The tablet was tested in a trial of 204 people over 64 weeks. Stopping because of adverse reactions was 6.9% on the tablet and 5.9% on placebo, and severe stomach or gut reactions were reported by 2% on the tablet and nobody on placebo.1 At NovoCare the tablet costs $149 a month for 1.5 mg, $199 for 4 mg and $299 for 9 mg and 25 mg, which makes it the cheapest form of either drug.5

    What does each cost?

    Here the two products differ most. Wegovy has a published self-pay price for people paying without insurance. Mounjaro does not: its reduced price requires commercial insurance that does not cover it.5,6

    A year of eachNov 20, 2026
    My situation
    Wegovy route

    Log each fill and what it cost, and the app adds up your year.

    Open the app

    Thirteen four-week fills make a year; the pill is twelve bottles of thirty tablets. Pen and pill figures are for a new patient at the regular self-pay prices, with the dose rising to 2.4 mg or 25 mg. Covered figures are the floor of each savings card.

    SituationWegovyMounjaro
    Commercial plan covers itAs little as $25 a month; up to $100 off a monthAs little as $25; up to $150 off a month and $1,950 a year
    Commercial plan does not cover itSelf-pay: $199 for the first two fills, then $349; $399 for 7.2 mgAs low as $499 a fill; up to $647 off a month and $8,411 a year
    No insuranceSelf-pay, the same prices; pill from $149No published price
    12-month subscription$249 a month, pen or pillNone
    List price of one fill$1,349.02

    NovoCare, Novo Nordisk press release and the Mounjaro savings page, read November 20, 2026.5,6,10

    For a first year without coverage, Wegovy pens come to $4,237: two fills at $199 and eleven at $349. On a 12-month subscription they come to $3,237, and twelve bottles of the pill to $3,338. Mounjaro at $499 a fill comes to $6,487, and only for people whose commercial insurance does not cover it.5,6,10

    The prices in detail

    Wegovy, without insurancePer fillPer weekThirteen fills
    Pen, first two fills for a new patient$199$49.75
    Pen, 0.25 to 2.4 mg$349$87.25$4,537
    Pen, 7.2 mg$399$99.75$5,187
    Pen, 12-month subscription$249$62.25$3,237
    Pen, 6-month subscription$299$74.75$3,887
    Pen, 3-month subscription$329$82.25$4,277

    NovoCare and Novo Nordisk press release of March 31, 2026. Per-week and yearly figures are our arithmetic.5,10

    Mounjaro has one figure to set against these: $499 a fill, or $124.75 a week and $6,487 for thirteen fills, for people with commercial insurance that does not cover it. The card reaches that price by taking off up to $647 a month, so by our arithmetic it covers a pharmacy price of up to $1,146 a fill, and it is limited to 13 fills and $8,411 in a calendar year.6

    In later years, without the two introductory fills, Wegovy pens cost $4,537 a year at the regular price. On every route Wegovy is cheaper than Mounjaro's $499 for someone paying out of pocket, by $1,950 to $3,250 a year.5,6,10

    The Mounjaro card asks for a prescription for an approved use consistent with the label, which is type 2 diabetes.2,6 For Medicare, Novo Nordisk describes a federal program that provides Wegovy to eligible Part D beneficiaries for $50 a month between July 1, 2026 and December 31, 2027.5 The pages on Wegovy cost and GLP-1 cost without insurance have every dose and program.

    What if you have both type 2 diabetes and obesity?

    Then each label has evidence in people like you. Wegovy's trial in adults with type 2 diabetes and obesity or overweight found 9.6% weight loss over 68 weeks, against 3.4% on placebo, with 67.4% losing at least 5%.1 Mounjaro's trials were all in type 2 diabetes: HbA1c fell 1.7 to 1.8 points with 6.3 to 7.8 kg of weight loss over 40 weeks.2

    The direct trial in diabetes adds the comparison at semaglutide's lower dose: over 40 weeks, 5.7 kg on semaglutide 1 mg and 7.6 to 11.2 kg on tirzepatide.4 What only Wegovy's label adds is outcome evidence in cardiovascular disease, from a trial in people without diabetes.1 Which of these weighs most is a decision for the prescriber.

    Can either be used under 18?

    Both, for different conditions. Wegovy is approved for weight reduction from age 12 in children with obesity, on the basis of a 68-week trial in 201 patients.1 Mounjaro is approved from age 10 for type 2 diabetes; in its trial of 97 patients the label reports reactions consistent with those in adults, with more vomiting, abdominal pain and low blood sugar.2

    Can you switch from one to the other?

    Neither label describes a switch between semaglutide and tirzepatide. Both start new patients at the lowest dose, and the timing and the dose of a change are the prescriber's decision.1,2 The page on switching from Wegovy to Zepbound shows how the levels of the two molecules overlap after a change, which applies to tirzepatide under either name.

    What happens when either is stopped?

    The drug leaves over weeks: about 5 to 7 weeks for semaglutide at Wegovy's doses and about 25 days for tirzepatide, by the half-lives in the labels.1,2 The pages on stopping tirzepatide and why people stop cover what the trials found afterwards and the reasons people give.

    What can these sources not tell you?

    Three things. No trial has compared Wegovy with tirzepatide in people with type 2 diabetes, the group Mounjaro is approved for. The two direct trials were open-label, and the larger difference in weight was found in a trial funded by the maker of tirzepatide. And averages describe groups: in Wegovy's main trial 47.9% of people lost at least 15% of their weight and 16.5% lost less than 5%.1,3,4

    Neither label ranks the two drugs. Each reports its own product against placebo, in the people it was approved for.1,2

    Short answers to common questions

    Is Mounjaro stronger than Wegovy?

    They are different drugs, so milligrams do not compare. In the trial that compared the molecules in obesity, tirzepatide produced 20.2% weight loss and semaglutide at Wegovy's doses 13.7% over 72 weeks.

    Which is better for weight loss, Wegovy or Mounjaro?

    Wegovy is the one approved for it. Mounjaro is approved for type 2 diabetes, and the tirzepatide product approved for weight is Zepbound. In both direct trials of the two molecules, tirzepatide led to more weight loss.

    Is Mounjaro approved for weight loss?

    No. Its one approved use is blood sugar control in type 2 diabetes.

    Which is better for type 2 diabetes?

    Mounjaro is the one approved for it. Wegovy is not approved for blood sugar control; the semaglutide product for diabetes is Ozempic.

    Do they work the same way?

    Partly. Both activate the GLP-1 receptor. Tirzepatide also activates the GIP receptor.

    Which has fewer side effects?

    The labels cannot say, because their trials differ. In the 40-week direct trial in diabetes, nausea was reported by 18% on semaglutide 1 mg and by 17% to 22% on tirzepatide.

    Which is cheaper without insurance?

    Wegovy, which has a self-pay price of $349 a month and $199 for a new patient's first two fills. Lilly publishes no self-pay price for Mounjaro.

    Which is cheaper with insurance?

    When the plan covers the product, both savings cards go as low as $25. Mounjaro's takes off up to $150 a month and Wegovy's up to $100.

    Can you take Wegovy and Mounjaro together?

    The labels do not provide for it. The label of tirzepatide for weight says it should not be used with any GLP-1 receptor agonist, which Wegovy is.

    Which stays in the body longer?

    Wegovy. Semaglutide has a half-life of about a week and tirzepatide about 5 days.

    What if I miss a dose?

    Wegovy: take it if the next dose is more than 2 days away, otherwise skip. Mounjaro: take it within 4 days, otherwise skip.

    Which protects the heart?

    Wegovy has a label indication for cardiovascular risk in adults with cardiovascular disease and obesity or overweight. Mounjaro's label has none.

    Is there a pill version?

    Of Wegovy, yes: a daily tablet from 1.5 mg to 25 mg. Mounjaro is injection only.

    Can teenagers take them?

    Wegovy from age 12 for obesity. Mounjaro from age 10 for type 2 diabetes.

    Is 2.4 mg of Wegovy the same as 2.5 mg of Mounjaro?

    No. They are different molecules. 2.4 mg is Wegovy's usual long-term dose, and 2.5 mg is Mounjaro's starting dose.

    Why does Wegovy's label show more weight loss than Mounjaro's?

    Because the trials differ. Wegovy's ran 68 weeks in people without diabetes, Mounjaro's 40 weeks in people with it. In the direct trial, tirzepatide led to more weight loss.

    How much more weight loss does tirzepatide give?

    In the direct obesity trial, 6.5 percentage points more over 72 weeks: 20.2% against 13.7% on semaglutide at Wegovy's doses. Tirzepatide for weight is sold as Zepbound.

    Does Wegovy lower blood sugar?

    Yes. Its label says it lowers blood glucose and can cause low blood sugar. It is not approved for blood sugar control.

    How long do the side effects last?

    For Wegovy, a single episode of nausea lasted a median of 8 days, diarrhea 3 days and vomiting 2 days in the pooled trials. The Mounjaro label gives no durations and says reports decreased over time.

    Does having no side effects mean the drug is not working?

    No. On Wegovy, people without stomach or gut events lost 15.7% against 17.3% for those with them. On Mounjaro the ranges were 6.2 to 13.3 kg against 6.2 to 14.9 kg.

    What does Wegovy's 7.2 mg dose add?

    A higher step after 2.4 mg. In its trials nausea was reported by 39% against 35% on 2.4 mg, and altered skin sensations by 22% against 6%.

    How much does each cost per week without insurance?

    Wegovy pens: $87.25 at the regular price and $62.25 on a 12-month subscription. Mounjaro: $124.75, and only with commercial insurance that does not cover it.

    Are side effects different in teenagers?

    Vomiting was more frequent in the young on both: 36% in Wegovy's trial from age 12, and 12% to 16% in Mounjaro's trial from age 10.

    Do older adults need a different dose?

    Neither label asks for one. Mounjaro's notes that greater sensitivity in some older people cannot be ruled out, and few people over 65 took part in Wegovy's weight trials.

    Were the direct trials blinded?

    No. Both were open-label, so participants knew which drug they were taking.

    Is Wegovy approved for a liver disease?

    Yes, for noncirrhotic MASH with moderate to advanced liver fibrosis in adults, under the accelerated approval pathway, on the basis of a trial of 800 adults with liver biopsies at 72 weeks.

    How many people lose 15% of their weight on Wegovy?

    In its main trial, 47.9% on Wegovy 2.4 mg against 4.8% on placebo. In its trial in people with type 2 diabetes, 25.1% against 4.3%.

    What did Mounjaro do to HbA1c?

    As the only diabetes medicine, it lowered HbA1c by 1.7 to 1.8 points over 40 weeks, and 78% to 85% of people finished below 7%, against 23% on placebo.

    Which direct trial used Wegovy's dose?

    The obesity trial, SURMOUNT-5, in which semaglutide was taken to 1.7 or 2.4 mg and tirzepatide to 10 or 15 mg. The diabetes trial used semaglutide 1 mg.

    Can Mounjaro be prescribed for weight loss?

    Its label does not include it, and its savings card asks for a prescription for an approved use. Zepbound is the tirzepatide product approved for weight.

    Which causes more nausea?

    The label rates are 44% for Wegovy and 12% to 18% for Mounjaro, from trials that differ in length and population. In the 40-week direct trial, 18% on semaglutide 1 mg and 17% to 22% on tirzepatide.

    Which causes more hair loss?

    Wegovy's label reports it in 3.3% against 1% on placebo. Mounjaro's lists it among reports after approval, without a rate.

    How fast can each reach its usual top dose?

    Wegovy reaches 2.4 mg in week 17. Mounjaro can reach 15 mg in week 21 at the earliest.

    What is the long-term dose of each?

    Wegovy: 1.7 mg or 2.4 mg for adults, with 7.2 mg as a further step. Mounjaro: 5 mg, or higher in 2.5 mg steps when more blood sugar control is needed, up to 15 mg.

    Does either have a subscription price?

    Wegovy does: $249 a month on a 12-month subscription, for the pen or the full-dose pill. Nothing comparable is published for Mounjaro.

    Does either need to be taken with food?

    No. Both injections can be given at any time of day, with or without meals. The Wegovy tablet is different: it is taken on an empty stomach.

    How the calculators work

    The head-to-head chart shows the two published trials that compared semaglutide with tirzepatide. The weight calculator multiplies your weight by each trial's average loss as a share of starting weight: the percentages the Wegovy label states; 7.2% and 9.1% for Mounjaro 5 mg and 15 mg, which we worked out from the label's kilograms and average starting weights; and the two arms of the direct obesity trial.

    The calendar places each label's dose steps at 4-week intervals from the date you enter. The reaction chart sets the adverse reaction table of each label side by side. The late-dose block applies each label's missed-dose rule and shows the level of each drug in our model: one compartment, with half-lives of 7 days for semaglutide and 5 days for tirzepatide. The cost calculator adds 13 four-week fills, or 12 bottles of the pill, at the prices the manufacturers published on November 20, 2026.

    The label trials differ in length, population and purpose, and only the two direct trials compare the molecules under the same conditions. One of those was in people without diabetes and the other tested semaglutide at 1 mg, so neither is a trial of Wegovy against Mounjaro in the people each is approved for.

    Sources

    1. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 1, 2, 5, 6.1, 8, 12, 14 and 16. accessdata.fda.gov
    2. MOUNJARO (tirzepatide) injection prescribing information, NDA 215866/S-052, revised April 2026. U.S. Food and Drug Administration; sections 1, 2, 5, 6.1, 7, 12, 14 and 16. accessdata.fda.gov
    3. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med 2025;393:26-36. doi:10.1056/NEJMoa2416394
    4. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 2021;385:503-515. doi:10.1056/NEJMoa2107519
    5. Novo Nordisk. NovoCare: Wegovy list price, self-pay prices, savings offer and Medicare program. Read November 20, 2026. novocare.com
    6. Eli Lilly and Company. Mounjaro savings and resources: savings card terms. Read November 20, 2026. mounjaro.lilly.com
    7. OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; section 1. accessdata.fda.gov
    8. ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 1 and 14. accessdata.fda.gov
    9. Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab 2022;24:94-105. doi:10.1111/dom.14551
    10. Novo Nordisk. Novo Nordisk launches first and only multi-month subscription program for FDA-approved Wegovy, offering savings of up to $1,200/year. Press release, March 31, 2026. novonordisk-us.com
    11. Patel H, Khunti K, Rodbard HW, Bajaj HS, Bray R, Kindracki Z, Rodríguez Á. Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials. Diabetes Obes Metab 2024;26:473-481. doi:10.1111/dom.15333

    Related analyses

    Log your doses and weight, whichever name is on the box.

    Open Dose Insider